TODAY’S HEADLINES:
- HealthExtras buys venture-backed PBM HospiScript for $100M (release)
- Urological device-maker NeoTract adds $7.4M (VentureWire)
- RNAi-drug startup Intradigm seeks $35M (VentureWire)
- Israel’s Arbel Medical raises $3.5M for tumor cryotherapy (release)
HealthExtras buys venture-backed PBM HospiScript for $100M — HospiScript Services, a Montgomery, Ala., prescription-benefits manager, agreed to be acquired by HealthExtras of Rockville, Md. HealthExtras will pay $100 million in cash for the venture-backed firm, which services the hospice industry.
HospiScript had raised at least $4 million in funding, according to VentureWire. That amount represents a 2005 round that involved Advantage Capital Alabama and Waveland NCP Alabama Ventures. The company declined to say more about its funding history.
Both companies manage the use of prescription drugs — HealthExtras for corporate, government and nonprofit health plans, HospiScript for hospices — in ways that are intended to reduce costs. HealthExtras said the acquisition will help it expand in the fast-growing hospice space.
Urological device-maker NeoTract adds $7.4M — Pleasanton, Calif.,-based NeoTract (no Web site), a devicemaker focused on urological problems, added $7.4 million to its first round of financing, VentureWire reports. The new funding brings that round to a total of $21.4 million.
New Enterprise Associates provided the cash.
NeoTract is working on a device to treat benign prostate hyperplasia, which is a non-cancerous growth of the prostate. The company doesn’t describe its device, although it says the product should enter clinical trials next year.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.
